Back to News
Market Impact: 0.42
Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer
Source: benzinga.com
Healthcare & BiotechProduct Launches
The FDA granted full approval for Eli Lilly's Inluriyo (imlunestrant), in combination with Verzenio (abemaciclib), for previously treated breast cancer patients. The approval expands Lilly's oncology portfolio and creates a new commercial opportunity in a significant breast-cancer treatment segment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
LLY0.82
More News
- Dozens of people sue GLP-1 drug companies over alleged vision loss
- Roche obesity drug shows 15.5% weight loss in diabetes trial
- Trump Says US Team Met With Iranians at UNGA
- Heidi CEO on AI in Healthcare, $900M valuation
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
- Guggenheim Names Top Stock Pick in Biotech Sector